智通财经APP讯，圣诺医药-B(02257)发布2025年中期业绩，其他收入12.4万美元，同比下降87.4%;公司 拥有人应占亏损369.8万美元，同比收窄91%;每股基本亏损0.04美元。 期内亏损减少主要归因于：截至2025年6月30日止六个月，按公平值计入损益的金融资产公平值变动亏 损减少;研发开支减少;行政开支减少;及按公平值计入损益的金融负债公平值变动亏损减少。 ...

Core Viewpoint - 圣诺医药-B reported a significant reduction in losses for the six months ending June 30, 2025, compared to the same period in the previous year, despite no product sales revenue generated [1] Financial Performance - The company recorded a loss of $3.4 million for the six months ending June 30, 2025, compared to a loss of $43.5 million for the same period in 2024 [1] - The reduction in losses is attributed to decreased fair value losses on financial assets, reduced R&D expenses, lower administrative expenses, and decreased fair value losses on financial liabilities [1] Strategic Initiatives - The company is actively seeking global and regional partnerships for STP705 and STP707, evaluating collaboration opportunities for the GalAhead™ platform assets, and establishing strategic alliances to enhance development capabilities [1] - Efforts are focused on maximizing the potential of the pipeline while minimizing development risks through shared expertise and resources [1] - The company is in discussions with several venture capital funds to establish a new entity aimed at advancing its product pipeline while optimizing R&D expenditures [1] Future Outlook - The company aims to submit a New Drug Application (NDA) for STP705 as early as 2027, with commercial success dependent on positive clinical data, regulatory approval, and robust intellectual property protection [1] - The commercialization strategy includes detailed market access planning, development of necessary infrastructure, and building partnerships [1]

期内亏损减少主要归因于：截至2025年6月30日止六个月，按公平值计入损益的金融资产公平值变动亏 损减少;研发开支减少;行政开支减少;及按公平值计入损益的金融负债公平值变动亏损减少。 圣诺医药-B(02257)发布2025年中期业绩，其他收入12.4万美元，同比下降87.4%;公司拥有人应占亏损 369.8万美元，同比收窄91%;每股基本亏损0.04美元。 ...

Clinical Development - Sirnaomics reported a positive clinical trial outcome for its lead candidate STP705, targeting two tumor indications: squamous cell carcinoma in situ (isSCC) and basal cell carcinoma (BCC) [17]. - The company is strategically prioritizing the advancement of isSCC into pivotal Phase IIb/III trials while retaining future development pathways for all indications [17]. - STP707 is currently undergoing Phase I clinical trials in the US for treating multiple solid tumors, with completion expected by the end of 2025 [18]. - STP705 has shown positive clinical results in the isSCC trial, leading to its evaluation in the medical aesthetics field, with an ongoing Phase I study in the US demonstrating excellent safety and early efficacy signals [18]. - STP705 has shown good efficacy in Phase IIa and IIb studies for isSCC and BCC, with plans to advance to later-stage clinical development [25]. - STP122G, based on the GalAhead™ mxRNA platform, is in Phase I trials, with initial safety data supporting continued clinical progress, expected to complete by 2026 [20]. - STP707 shows good tolerance and therapeutic effects, especially in pancreatic cancer patients, with a Phase I trial involving 50 patients expected to complete by the end of 2025 [26]. - The company is advancing STP125G and STP144G into clinical development, with STP125G targeting ApoC3 for hypertriglyceridemia and cardiovascular diseases, and IND submission planned for 2025 [29]. Technology and Innovation - Sirnaomics utilizes a dual delivery system (PNP and GalAhead) to advance a diverse pipeline addressing unmet medical needs across oncology, fibrosis, aesthetic medicine, anticoagulation, and cardiovascular metabolic diseases [17]. - The GalAhead™ delivery platform is being researched for various liver cell-related diseases, utilizing mxRNA and muRNA therapies for subcutaneous administration [19]. - The PNP delivery platform is clinically validated and supports therapy development across oncology, fibrotic diseases, and medical aesthetics [31]. - The GalAhead™ platform has shown strong clinical validation, with STP122G demonstrating excellent safety in initial clinical cohorts [39]. - The company is positioned as a pioneer in the RNA interference field, focusing on dual-gene targeting projects to address significant scientific and commercial interest [20]. Financial Performance - For the six months ended June 30, 2025, the company reported a loss of $3.4 million, a significant improvement from a loss of $43.5 million for the same period in 2024, representing a reduction of approximately 92% [48]. - The group’s loss decreased from $43.5 million for the six months ended June 30, 2024, to $3.4 million for the six months ended June 30, 2025, primarily due to reduced fair value losses on financial assets and lower R&D and administrative expenses [62]. - The company reported a net loss of $3,388,000 for the six months ended June 30, 2025, compared to a net loss of $41,065,000 for the same period in 2024, indicating a significant improvement [161]. - The total comprehensive loss for the period was $3.410 million, compared to $43.887 million in the previous year [154]. - The company had no product sales revenue for the six months ended June 30, 2025 [50]. - The company recognized share-based payments totaling $1,599,000 during the reporting period [159]. Cost Management - Research and development expenses decreased by $11.3 million or 79% to $3.0 million for the six months ended June 30, 2025, attributed to a strategic focus on developing STP705 and STP122G while pausing other projects [59]. - Administrative expenses were reduced by $7.6 million or 75% to $2.6 million for the six months ended June 30, 2025, due to restructuring strategies and cost-saving measures [57]. - Employee costs totaled $2,710,000, a decrease of 68% from $8,459,000 in the prior year, with salaries and other allowances dropping from $6,402,000 to $2,248,000 [176]. Strategic Partnerships and Licensing - The company is actively engaging potential partners to accelerate innovative medical aesthetics projects based on STP705 [25]. - The company aims to leverage proprietary technology through strategic licensing to empower biopharmaceutical partners while advancing its internal pipeline [21]. - The company is actively seeking global and regional partnerships for STP705 and STP707 to enhance development capabilities and reduce risks [40]. Restructuring and Financial Strategy - A comprehensive restructuring plan has been implemented to enhance operational efficiency and extend financial runway [38]. - The company is exploring additional financing opportunities and evaluating strategic options, including selective divestiture of non-core assets [38]. - The company is actively seeking external financing through equity and debt to supplement its cash reserves [162]. - The company is exploring business development opportunities for its pipeline assets to enhance revenue generation [162]. Employee Incentives and Share Options - The group has adopted a pre-IPO equity incentive plan, restricted share unit plan, and stock option plan to incentivize eligible employees [81]. - The pre-IPO equity incentive plan aims to attract and retain outstanding talents for the group [82]. - The plan allows for the reallocation of shares if rewards expire, lapse, or are canceled, enabling those shares to be used for new rewards [90]. - The stock option plan aims to attract and retain talent, align interests with shareholders, and provide additional incentives for performance [117]. - The company granted a total of 8,904,023 share options under the share option scheme adopted on June 28, 2022 [6]. Shareholder Information - The company did not declare any interim dividend for the reporting period [149]. - The company has not purchased, sold, or redeemed any of its listed securities during the six months ending June 30, 2025 [140]. - The company plans to grant a total of 8,137,550 further share options, representing approximately 7.74% of the issued shares [9]. Legal and Compliance - The company has made no significant litigation or arbitration claims as of June 30, 2025 [143]. - The company is currently undergoing arbitration proceedings related to a claim against the investment manager, with the arbitration tribunal established on November 8, 2024 [184]. - The group has significant uncertainty regarding its ability to continue as a going concern due to the potential failure to implement restructuring plans [164].

Group 1 - The Hong Kong biotechnology stocks experienced a collective decline, with notable drops in several companies [1] - WuXi AppTec (02126) saw a decrease of 12.95%, closing at 4.840 [2] - BioNTech (06952) fell by 12.53%, with a latest price of 13.750 [2] Group 2 - Other companies such as Valiant (09887) and Beihai Kangcheng (01228) also reported significant declines of 9.93% and 9.75% respectively [2] - The decline extended to companies like Saint Noble (02257) and MIRXES (02629), which dropped by 9.64% and 8.43% [2] - Overall, the biotechnology sector is facing downward pressure, impacting multiple firms [1]

圣诺医药宣布，该公司将于2025年8月28日(星期四)举行董事会会议，藉以(其中包括)考虑并批准公司及 其附属公司截至2025年6月30日止六个月的中期业绩及其发布。 智通财经APP获悉，香港联交所最新资料显示，8月26日，圣诺医药-B(02257)股东将股票存入招银国际 证券，存仓市值1.81亿港元，占比16.67%。 ...

圣诺医药宣布，该公司将于2025年8月28日(星期四)举行董事会会议，藉以(其中包括)考虑并批准公司及 其附属公司截至2025年6月30日止六个月的中期业绩及其发布。 香港联交所最新资料显示，8月26日，圣诺医药-B(02257)股东将股票存入招银国际证券，存仓市值1.81 亿港元，占比16.67%。 ...

香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部份 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 Sirnaomics Ltd. 聖 諾 醫 藥 * （ 於開曼群島註冊成立的有限公司） （股份代號：2257） 承董事會命 Sirnaomics Ltd. 主席兼獨立非執行董事 黃夢瑩 香港，2025年8月18日 於 本 公告 日 期 ， 董 事會 包 括 執 行董 事 潘 洪 輝 博士 、 非 執 行 董事 歐 陽 雲 龍先 生 ， 以及 獨 立 非 執 行董 事 黃 夢 瑩女 士 、 于 常 海博 士 、 王 宇 山先 生 及 張 鵬博 士。 * 僅供識別 董事會會議通告 Sirnaomics Ltd.（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於2025年 8 月 28 日（ 星 期 四 ）舉 行 董 事 會 會 議 ， 藉 以（ 其 中 ...

Core Viewpoint - The Hong Kong pharmaceutical stocks are experiencing a strong performance, with notable gains in several companies [1] Company Performance - Sanofi Pharmaceutical-B (02257.HK) increased by 5.50% - Kangfang Biotech (09926.HK) rose by 5.23% - Genscript Biotech (01952.HK) saw a rise of 4.38% - Fudan Zhangjiang (01349.HK) grew by 4.21% [1]

Group 1 - The Hong Kong pharmaceutical stocks showed a strong performance, with several companies experiencing significant gains [1] - Baset Pharmaceutical (02616.HK) increased by 9.86%, indicating a robust market response [1] - Other notable gainers included Charoen Pokphand International (03839.HK) with a rise of 7.06%, Sanofi Pharmaceutical (02257.HK) up by 6.93%, and Weiya Biotechnology (01873.HK) which saw a 5.80% increase [1]